Press Releases

Media Inquiries - media@caredxinc.com

Date	Title and Summary	Additional Formats
Toggle Summary Feb 07, 2018	CareDx to Participate in Upcoming Investor Conferences BRISBANE, Calif , Feb. 07, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag , Chief	View HTML CareDx to Participate in Upcoming Investor Conferences 22.5 KB
Toggle Summary Feb 05, 2018	CareDx Leadership in cfDNA Highlighted at CEoT CareDx symposium and panel presentations will showcase AlloSure experience	View HTML CareDx Leadership in cfDNA Highlighted at CEoT 25.2 KB
Toggle Summary Feb 01, 2018	First Patient Enrolled in AlloSure Registry Innovative AlloSure registry brings standardization to transplant centers	View HTML First Patient Enrolled in AlloSure Registry 19.7 KB
Toggle Summary Jan 16, 2018	TRIO Honors Peter Maag with Transplant Innovation Award Transplant Patient Organization Recognizes AlloSure's Impact	View HTML TRIO Honors Peter Maag with Transplant Innovation Award 19.3 KB
Toggle Summary Jan 08, 2018	CareDx Reports Preliminary Fourth Quarter and FY2017 Financial Results 32 Transplantation Centers Offering AlloSure	View HTML CareDx Reports Preliminary Fourth Quarter and FY2017 Financial Results 25.5 KB
Toggle Summary Nov 20, 2017	CMS Releases 2018 Clinical Laboratory Fee Schedule AlloMap 2018 Rate Increase Confirmed	View HTML CMS Releases 2018 Clinical Laboratory Fee Schedule 16.7 KB
Toggle Summary Nov 15, 2017	CareDx Further Simplifies its Balance Sheet BRISBANE, Calif. , Nov. 15, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients, today reported that it has agreed to	View HTML CareDx Further Simplifies its Balance Sheet 15.6 KB
Toggle Summary Nov 09, 2017	CareDx Reports Third Quarter 2017 Financial Results BRISBANE, Calif. , Nov. 09, 2017 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported financial results for	View HTML CareDx Reports Third Quarter 2017 Financial Results 72.9 KB
Toggle Summary Nov 02, 2017	CareDx to Participate in Upcoming Investor Conferences BRISBANE, Calif. , Nov. 02, 2017 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag ,	View HTML CareDx to Participate in Upcoming Investor Conferences 19.1 KB
Toggle Summary Oct 31, 2017	CareDx Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) BRISBANE, Calif. , Oct. 31, 2017 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that, as an inducement	View HTML CareDx Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 14.6 KB